Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cormedix ( (CRMD) ) just unveiled an update.
On August 12, 2025, CorMedix Inc. completed a private placement offering of $150 million in convertible senior notes due 2030, exempt from registration under the Securities Act of 1933. The company entered into an indenture with U.S. Bank Trust Company to govern the notes, which have an initial conversion rate of 74.2515 shares of common stock per $1,000 principal amount.
The most recent analyst rating on (CRMD) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Cormedix stock, see the CRMD Stock Forecast page.
Spark’s Take on CRMD Stock
According to Spark, TipRanks’ AI Analyst, CRMD is a Neutral.
Cormedix’s overall stock score is influenced by a challenging financial position, marked by ongoing losses and negative cash flows. Despite technical indicators showing potential downward pressure, the recent earnings call provides a positive outlook with record-breaking revenue and strategic growth initiatives. However, valuation concerns and operational challenges remain significant obstacles.
To see Spark’s full report on CRMD stock, click here.
More about Cormedix
Average Trading Volume: 2,183,310
Technical Sentiment Signal: Buy
Current Market Cap: $751.7M
Learn more about CRMD stock on TipRanks’ Stock Analysis page.